BriaCell Therapeutics Corp. announced a new remarkable responder in Phase 2 study of the Bria-IMT?? combination regimen.

BriaCell's clinical team reported a patient with extensive metastatic breast cancer who had failed all available therapies. The patient had cancer behind the eye, causing proptosis (eye-bulging) and significant pain that were both resolved with BriaCell's treatment. Additional survival updates and clinical data sets on the entire Phase 2 study cohort will be presented at the San Antonio Breast Cancer Symposium on December 6th and 7th, 2023.

The noted responder, a post-menopausal metastatic breast cancer patient (the Remarkable Responder), experienced a remarkable improvement of proptosis caused by breast cancer tumors behind the eye, resulting in significant pain reduction in the ocular region. Her disease is characterized as positive for hormone receptor and 3+ for HER2. The woman had extensive metastatic disease (breast cancer tumors that have migrated to other areas of the body) including the bones of the spine, pelvis, sternum, the skull, and face, which included proptosis of the right eye from which the patient was clinically blind in that eye.

The patient was heavily pre-treated (7 prior regimens) highlighting the remarkable nature of her response on BriaCell?s treatment despite her very advanced cancer stage. Her last disease progression was recorded in August 2023. The patient started on BriaCell?s Bria-IMT?

combination therapy on October 4, 2023 and has received only 3 cycles of therapy. The Bria-IMT? combination regimen has been well tolerated and the patient remains on treatment.

BriaCell had previously reported a similar case of a remarkable response with 100% resolution of an eye-bulging orbital tumor. This particular patient had received (and failed) 12 regimens with 16 agents (incl. 13 chemotherapies) prior to BriaCell?s treatment, again adding to the remarkable nature of her response.